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Abstract 
Background: Low detection and nonadherence are major problems in current management 
approaches for patients with suspected atrial fibrillation (AF). Mobile health (mHealth) devices 
may enable earlier AF detection, and improved AF management. 
Objectives: To investigate the effectiveness of AF screening in a large population-based cohort 
using smart device based photoplethysmography (PPG) technology, combined with a clinical 
care AF management pathway using a mHealth approach. 
Methods: AF screening was performed with smart devices using PPG technology (Huawei 
Technologies Co., Ltd., Shenzhen, China) which were made available for the population aged 
over 18 years across China. Monitoring for at least 14-days with a wristband (HONOR BAND 4) 
or wristwatch (HUAWEI WATCH GT, HONOR WATCH), was allowed. The patients with 
‘possible AF’ episodes using the PPG algorithm were fu ther confirmed by health providers 
among the MAFA (mobile AF App) Telecare center and network hospitals, with clinical 
evaluation, electrocardiogram (ECG), or 24-h Holter. 
Results: There were 246,541 individuals who downloaded the PPG screening App, and 187,912 
individuals used smart devices to monitor their pulse rhythm between October 26, 2018 and May 
20, 2019.  Among those with PPG monitoring (mean age 35 years, 86.7% male), 424 (mean age 
54 years, 87.0% male) received a ‘suspected AF’ notification (424/187,912, 0.23%). Of those 
effectively followed up, 227 individuals (227/262, 87.0%) were confirmed as having AF, with 
the positive predictive value (PPV) of PPG signals being 91.6% (95% confidential interval (CI) 
91.5%-91.8%). Both ‘suspected AF’ and ‘identified AF’ markedly increased with age (p for 
trend <0.001), and individuals in Northeast China had the highest proportion of detected AF of 
0.28% (95%CI 0.20-0.39). Of the individuals with identified AF, 216 (216/227, 95.1%) 
subsequently entered a programme of integrated AF management using a mobile AF application 
(mAFA); approximately 80% of ‘high risk’ patients were successfully anticoagulated. 
Conclusions: Based on the present study, continuous home-monitoring with smart device based 
PPG technology could be a feasible approach for AF screening. This would help efforts at 
screening and detection of AF, as well as early interventions to reduce stroke and other AF-
related complications. 
 
Condensed Abstract: The study aimed to determine the feasibility of AF screening in a large 
population-based cohort using smart device based photo lethysmography (PPG) technology, 
combined with a clinical care AF management pathway. There were 187,912 individuals used 
smart devices to monitor their pulse rhythm between October 26, 2018 and May 20, 2019. 87.0% 
were confirmed as having AF, with the PPV of PPG signals being 91.6%.  Following entry into a 
programme of integrated AF management using a mobile AF application, approximately 80% of 
high risk patients were successfully anticoagulated. Based on the present study, continuous 
home-monitoring with smart device based PPG technology could be a feasible approach for AF 
screening. This would help efforts at screening and detection of AF, as well as early 
interventions to reduce stroke and other AF-related complications.  
 
Keywords: atrial fibrillation, screening, photoplethysmography, integrated care 
 
Abbreviations: 
AF = atrial fibrillation 
ECG = electrocardiogram  
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PPG = photoplethysmography  
USPSTF = US Preventive Services Task Force 
mAF App = mobile atrial fibrillation application 
PPV = positive predictive value  
CHA2DS2-VASc = congestive heart failure, hypertensio , age ≥75, diabetes, stroke, vascular 
disease, age 65–74, and sex category (female) 
HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalised ratio, elderly, drugs/alcohol concomitantly 
SAMe-T2T2R = sex female, age, medical history, treatment, tobacco use, race 
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Introduction 
Low detection and nonadherence are major problems in current management approaches 
for patients with suspected atrial fibrillation (AF). AF screening has been advocated with the 
recognition that this could ultimately reduce AF-relat d stroke and death, with the initiation of 
treatments such as oral anticoagulation, and other risk-factor modifications to reduce AF-related 
complications and arrhythmia progression [1]. Indeed, active screening strategies could improve 
detection of AF in comparison with routine care. Nonetheless, a systematic screening strategy for 
AF did not show an obvious advantage to opportunistic screening, using pulse palpation and a 
12-lead electrocardiogram (ECG) [2]. 
Recent advances in mobile and wearable devices provide a possible solution [3].  New 
technology has been developed to improve the early detection of AF and among these, 
photoplethysmography (PPG) and single lead ECG recordings are promising methods available 
to the public for detecting AF [4]. In the STROKESTOP study, a handheld ECG recorder for 
intermittent ECG recordings over 2 weeks improved AF diagnosis in high-risk population aged 
75-76 years old [5]. Another AF screening approach wit twice-weekly single-lead ECG 
recorders among those aged over 65 years identified more incident AF than routine care, but 
adverse clinical events (including stroke, thromboembolism, death, etc.), were not significantly 
different over a 52-week follow-up period [6]. Henc, it has been questioned how AF screening 
could have a more beneficial effect on subsequent AF management, and the U.S. Preventive 
Services Task Force (USPSTF) recently concluded that the current evidence was insufficient to 
assess the balance of benefits and harms of screening for atrial fibrillation with ECG [7].  
Similarly, current U.K. National Screening Committee policy recommends that population 
screening for AF should not be offered by the National Health Service [8].  Thus, more evidence 
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on strategies for improving AF screening, detection and subsequent management to reduce AF-
related adverse outcomes is needed. 
Approaches using random brief ECG screening could possibly miss those individuals 
with a low burden of (paroxysmal) AF, and long-term continuous screening may overcome the 
problem. An ECG skin adhesive patch, which could provide 14-day monitoring, resulted in a 
higher proportion of AF diagnosis compared with delay d monitoring; however, nearly one third 
of subjects refused to use the ECG patch, and some individuals reported skin irritation, resulting 
in early discontinuation structured management [9]. A smartwatch strap with single ECG sensor 
may be a more comfortable method, with 93% sensitivity and 84% specificity of AF diagnosis 
compared to a 12 lead ECG, but only 66% of monitored signals could be interpretable with the 
app algorithm alone 10].  Thus, the stability of the signal quality and motion artifacts are 
additional considerations when considering an ECG-based approach to AF screening. 
In contrast, increasing evidence supports PPG-monitori g for AF screening [11,12,13]. 
Mass screening for AF has been carried out using smartphone cameras with reliable PPG signals 
[14]. In our previous pilot study, both smartphones and smart bands with PPG demonstrated 
good performance in detecting AF [15].  Hence, it may be more practical to screen for AF in a 
large population using a PPG-based smart device, esp cially if integrated with a structured 
management program for AF, again based on smart technology.  In a pilot study of such a 
structured management program, we showed that a mHealth t chnology-supported AF 
application (mAF App) could be developed and validate , integrating patient clinical decision 
support tools, guideline-based treatment, educationl materials and patient involvement 
strategies with self-care protocols and structured follow-up [16].  
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In the Huawei Heart Study, our aim was to screen for AF and report the incidence of AF 
identified, as well as the proportion of AF patients being anticoagulated.  We hypothesized that 
use of a mobile health PPG technology approach would facilitate AF screening, and the 
associated App-based integrated AF care approach would result in early AF detection and 
increased use of oral anticoagulation. The latter could have the potential in reducing AF-related 
complications such as stroke and mortality [17]. 
Methods 
The Mobile health technology for improved screening, patient involvement and 
optimizing integrated care in Atrial Fibrillation (MAFA II) study program was developed to 
verify a screening and integrated care approach to improving AF management. The ‘Pre-MAFA’ 
study was the first stage of the MAFA II program, using HUAWEI smart technology (herein 
referred to as the ‘Huawei Heart Study’) to test the feasibility of continuous home-monitoring 
with PPG technology in a large population [18] (Online Figure 1). Identified AF patients were 
then transferred into a structured program of holistic and integrated care using a smartphone App 
(mAF App) [18].  The present report only focuses on the ‘Huawei Heart Study’, which is the AF 
screening component (‘Pre-MAFA’) of this programme. 
AF screening with smart devices using PPG technology (Huawei Technologies Co., Ltd., 
Shenzhen, China) were made available for the population ged over 18 years across China. 
Inclusion criteria included use of the Huawei phone (Android 5.0 or higher), and one of 
following smart devices: Huawei Watch GT (Version 1.0.3.52 or higher), Honor Watch (Version 
1.0.3.52 or higher), and Honor Band 4 (Version 1.0.0.86 or higher). The participants needed to 
have compatible HUAWEI smart device(s) and phone. Exclusion criteria included age <18 years, 
and inability to use smart phone or devices. At least 14-day monitoring with smart devices based 
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on PPG (with the PPG algorithm developed by Huawei) as proposed. The study was approved 
by the Central Medical Ethic Committee of Chinese PLA General Hospital (Approval number: 
S2017-105-02) and registered at the Chinese Clinica Tri l Registry (ChiCTR) website 
(ChiCTR-OOC-17014138).  Subjects could freely download the app in the HUAWEI Appstore. 
All subjects who were interested in the study were informed of the study design and gave their 
informed consent before entering the study. Adults downloading the AF screening App across 
China mainland were enrolled into present Pre-MAFA study analysis between October 26, 2018 
to May 20, 2019. 
AF detection 
An AF screening App was developed based on the Android Operating System (Google, 
Mountain View, California). The individuals could initiate rhythm monitoring with AF screening 
App using smart devices. The users could also start directly AF detection with MAFA (Figure 
1). The irregular pulse wave would be screened with ac ive or periodic measuring using the PPG 
algorithm. Individuals could initiate active measurements at rest, and 45-second PPG signals 
would be collected. Periodic measurements would be automatically be taken every 10 minutes, 
and 60-second PPG signals would continuously be coll cted. The discrimination rule of the PPG 
algorithm and notification of ‘suspected AF’ is shown in Figure 2. A notification of ‘suspected 
AF’ would be delivered, once the proportion of ‘possible AF’ episodes was 100%, when ten 
measurements were initiated. In the case of PPG measur ments >10, the threshold T was set to 
ensure that the positive predictive value of making a decision was over 0.85, and the sensitivity 
would be as high as possible. The T could be adjusted to a more suitable value with enough 
study data were collected. The notification of ‘suspected AF’ would also be delivered once the 
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proportion of ‘possible AF’ episodes over threshold T in the setting of PPG measurements was 
>10 (Figure 2). 
AF diagnosis and management 
The individuals with ‘suspected AF’ episodes using the PPG algorithm were further 
confirmed by the health providers using the MAFA Telecare center and network hospitals, with 
clinical evaluation, ECG, or 24-h Holter (Online Figure 2). Individuals with ‘identified AF’ 
would be managed according to an App-based AF integra d care pathway approach, based on 
the ABC (‘A’ Avoid stroke, ‘B’ Better symptom management, and ‘C’ Cardiovascular risk and 
comorbidity management) pathway [19]. The ABC pathway approach has been associated with 
improved clinical outcomes in various independent cohorts [20,21,22]. 
Statistical analysis 
Continuous variables were tested for normality by the Kolmogorov-Smirnov test. Data 
with a normal distribution were presented as a mean (standard deviation, SD). Data with a non-
normal distribution were presented as median (interquartile range, IQR) and were analyzed by 
using Kruskal-Wallis test. χ2 test was used for categorical variables.  Data visual zation analysis 
was utilized for the enrollment across China with ECharts, version 4.2.1 (Apache Software 
Foundation). 
The “irregular pulse rhythm” by PPG algorithm was observed, and the predictive ability 
of AF with PPG algorithm was analyzed in comparison with the confirmed diagnosis of AF 
using clinical evaluation, ECG, or 24-h Holter by the health providers from the MAFA Telecare 
center and network hospitals. The proportion of "identified" AF from the general population 
screening that were enrolled into the subsequent main MAFA integrated care trial was calculated 
to explore the feasibility of the approach AF screening combined with integrated care. 
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The monitoring method for first “suspected” AF was calculated, and “suspected” AF 
episodes in relation to measurement method, the automatic periodical measurements and active 
measurements, were analyzed using the Kruskal-Wallis test for the comparations among 
different measurement approaches. Moreover, the influe ce of the continuous monitoring time 
on first detected "suspected" and “identified" AF episodes were investigated, to explore the 
optimal screening "window".  Incident AF was analysed in relation to age strata, sex, and region. 
Finally, AF management among individuals with "identified" AF enrolled into an App-based AF 
integrated care structured programme with the mAFA trial, were investigated, including their 
stroke risk, bleeding risk, and the likelihood for good anticoagulation control. Anticoagulant use 
classified by risk assessment is reported, while the changes on oral anticoagulant use among 
different risk strata were compared. 
A 2-sided P-value <0.05 was considered as statistically significant. The 95% confidential 
intervals (CIs) were calculated with Wilson score mthod without continuity correction [18]. 
Statistical analysis was performed using IBM SPSS Statistics, version 25.0 (SPSS Inc.). 
Results 
There were 246541 individuals who downloaded the PPG screening app, and 187912 
individuals used smart devices to monitor their pulse rhythm between October 26, 2018 and May 
20, 2019. Enrollment and baseline characteristics are summarized in Online Figure 3 and Table 
1.  
Monitoring method and identification 
There were 265,139 ‘suspected AF’ episodes for 424 subjects (mean age 54 years, 87.0% 
male) among 187,912 subjects screened (mean age 35 years, 86.7% male). Of the ‘suspected AF’ 
subjects, 262 (262/424, 61.8%) were effectively followed up with full medical history, physical 
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examination, ECG, or 24-hour Holter (Figure 3). Of those with full assessment, 227 (227/262, 
87.0%) subjects were confirmed as having AF. Cardiac rhythms of ‘suspected AF’ episodes are 
summarized in Online Figure 4.  
There were 186,956 ‘identified AF’ episodes for the227 subjects and 203,985 episodes 
for the 262 ‘suspected AF’ subjects. The positive predictive value (PPV) of PPG signals was 
91.6% (95%CI 91.5%-91.8%). Individuals with ‘suspected AF’ episodes were mostly monitored 
using automatic periodical measurements (periodical vs. active measurements, 37.0% vs. 7.6%, 
p<0.001) (Online Figure 5, Online Table 1). 70.8% of AF episodes were found within 14 days, 
but nearly one third of AF episodes were recorded after two weeks (Figure 4). The distribution 
of monitoring time in the whole cohort is shown in O line Figure 9. Supplementary material 
online summarizes user reported adverse events (Online Table 2), a comparison performance of 
the various smart devices utilized in PPG screening (Online Table 3), and the standby time of the 
various smart devices with or without PPG screening (Online Table 4). They show generally 
high specificity (approx. 99%), sensitivity (100%) and accuracy (>99%), irrespective of smart 
device used. 
AF episodes in the general population 
Incident ‘suspected AF’ and ‘identified’ AF markedly increased with age (p for trend 
<0.001) (Figure 5). The highest proportion of AF episodes was among the elderly, ie. those aged 
over 65 years, with 2.78% (95% CI 2.28-3.38) being ‘suspected AF’, and 1.70% (1.31-2.19) 
being ‘identified’ AF (Figure 5). There was a higher risk of incident AF in indiviuals aged over 
55 years compared to those aged under 55 years (2.62% vs 0.17%; p<0.001). The prevalence of 
detected AF was highest in Northeast China compared to other regions in China (p<0.001, 
Online Figure 6). 
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AF management 
216 (216/227, 95.1%) individuals with ‘identified AF’ were entered into an App-based 
AF integrated care structured program with MAFA (Figure 3); of these, 29 (29/216,13.42%) 
who initiated MAFA to monitor the rhythm were subsequ ntly found to have a known AF 
diagnosis.  Clinical decision support tools were provided for doctors and patients (Online Table 
5). The patient’s personized stroke risk was assessed with the CHA2DS2-VASc score (mean, 
SD, 1.07, 1.09), while bleeding risk was assessed uing the HAS-BLED score (mean, SD, 0.35, 
0.52), respectively. Their likelihood for good anticoagulation control was assessed using the 
SAMe-T2T2R score (mean, SD, 3.71, 0.66). Distribution of subjects according to these scores 
are shown in Online Table 5. 
Overall, 79.6% of patients at high-risk were anticoagulated (Table 3). There was no 
difference in risk characteristics and anticoagulant use among high-risk individuals comparing 
individuals with newly detected AF and with known AF (Table 2). 
Discussion 
In the Huawei Heart Study, we show that PPG-based smart devices were feasible as an 
easy-to-use screening tool in this population-based, large-scale AF screening study, with a good 
performance for AF detection (Central Illustration ). Second, the heterogeneity of incident AF, 
in relation to regions and age, suggests the need for a different prevention approaches based on 
local population requirements. Thus, the use of mobile and wearable devices could provide a 
simple, feasible and practical mHealth approach for AF early detection, that can be followed by 
guideline-guided app-based intervention. 
AF management integrated with AF detection might provide more benefits for patients. 
Previous studies have demonstrated that smart devices (smartphone, E-patch, handing device, 
13 
wrist band, etc.) can be used for AF detection [5,6,9,10,11,12,13,14,15]; however, an integration 
with subsequent clinical management of ‘screened AF’ was lacking.  In the present Huawei 
Heart Study (Pre-MAFA), 95.1% of individuals with identified AF, who screened from general 
population, were entered into an AF integrated careprogram with MAFA, providing guideline-
guided intervention and leading to a high proportion of patients being successfully 
anticoagulated. 
The clinical decision support within the MAFA program with CHA2DS2-VASc, HAS-
BLED, and SAMe-TT2R2 scores on the MAFA platform provides risk-assessment advice for 
doctors, and facilitates sharing decision making for the patients.  In this study, approximately 
80% of ‘high risk’ AF patients in MAFA received oral nticoagulants (OACs), which is a 
marked improvement over prior reports of suboptimal thromboprophylaxis in prior Chinese 
cohorts [23,24,25]. Thus, AF screening, combined with a clinical integrated care program for 
detected AF, may translate to better treatment and prevention of AF-related major complications, 
such as stroke and death. 
The continuity, comfort and the stability of monitor ng signals, that are not influenced by 
motion, are challenges for a good predictive ability for AF using smart devices.  A lower 
accuracy in ambulatory than sedentary patients has been observed with a Cardiogram app using a 
wristwatch [26]. Indeed, only 66% of monitoring signals could be interpretable with a single-
lead ECG wristwatch by App algorithm alone [10]. In the present study, 91.6% of PPG positive 
signals by algorithm were confirmed as AF. The improved screening ability of AF with the 
present PPG-based smart devices possibly stems from frequent, continuous monitoring and the 
good quality of monitoring signals. With a single battery life (average standby time with 
HUAWEI smart devices is 6.7 days with PPG screening), periodic measurements could be taken 
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automatically every 10 minutes in this study, which was far more frequent than obtained from 
the Apple watch in the Apple Heart Study, with measurements only taken every two hours at 
baseline, which was then increased to every 16 minutes once an irregular tachogram was 
detected [27].  In addition, the discrimination of the PPG algorithm could possibly contribute to 
the better detection of AF, as shown in this study. 
Our study found that most AF episodes were found within 14 days, but nearly one third 
of AF episodes were detected on monitoring after 2 weeks. In the case of paroxysmal AF, the 
time to the first detection has been inversely related to AF burden [28,29]. Automatic periodic 
PPG measurements have the advantage of active measurements in the search for AF episodes in 
this study, suggesting that a continuing monitoring approach was better than single-point 
intermittent monitoring. Our study also supports the possibility that PPG-based wrist-worn 
wearables (watches, bands) would be the good choices for AF screening [30,31]. 
In this study, the prevalence of ‘suspected AF’ of 0.2% in the general population was 
lower than the 0.5% reported in Apple Heart Study [27]. There are possibly several reasons for 
this. This was much younger population with 1.8% who were aged over 65 years old in the 
present study, compared to 6% being aged over 65 years old in Apple Heart Study [27].   There 
is also a lower incidence and prevalence of AF in the Chinese population compared to the 
Western population [32,33]. The strict discrimination rule of the PPG algorithm may also 
contribute to the low prevalence of detected AF. 
However, a trend for increasing detected AF with aging was evident in the Chinese 
population, with a fifteen-fold (2.62/0.17) greater AF risk in those aged >55 years compared to 
those aged < 55 years; this difference was only eight-fold (4.5/0.53) in the Apple Heart Study.  
AF screening might be much more beneficial for those at high-risk of AF, (e.g., population with 
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age >55 years). The cost effectiveness of AF screening related to different population risks 
would need to be ascertained in future studies.  In addition, we noted a geographical difference in 
incident AF in the present study, with the highest prevalence of AF in Northeast China that was 
consistent with the distribution of clinical risk factors for AF (Online Table 6). The heterogeneity 
of risk factors incident AF may suggest the need for different prevention approaches in different 
settings based on local clinical risk profiles. 
Strengths and limitations 
There were several limitations in this study. We were not doing a trial of the efficiency of 
AF screening since the current study relates to the "yield" with the current technology and the 
specificity of the diagnosis, rather than sensitivity.  Although we had strict follow-up procedures 
for ‘suspected AF’, there were 38% of individuals with ‘suspected AF’ who could not be 
effectively followed up, which would decrease the proportion of identified AF.  For the PPV 
calculation with PPG signals, we did not have real-time 12-lead ECG data synchronized with 
PPG-based smart devices. Indeed, it would be difficult to make all individuals have a 14-day 12-
lead Holter examination with a mass population screening study. However, the diagnosis of AF 
was confirmed with medical history, physical examination, ECG or 24-Holter by healthcare 
providers.  While we aimed to focus on newly diagnosed or detected AF, 29 subjects were 
subsequently found to have known AF, as was also seen in the Apple Heart Study, where 15% 
with known AF entered that study [27]. Also, incident AF detection in present study might be 
impacted by the availability of smart phones and devices. In the present study, 24% of subjects 
downloaded the App but were without compatible smart devices.  The underlying reason(s) may 
be multifactorial; however, 187,912 individuals were ntered into the study, suggested the PPG-
based smart device could still be a feasible screening strategy. Finally, we did not report on hard 
16 
outcomes (stroke, death, etc) impacted with AF screening approach in the present Pre-MAFA 
study and would be further reported in the future from the ongoing MAFA II trial [18].   
Conclusion 
Continuous home-monitoring with smart device-based PPG technology is a feasible 
approach for screening and early detection of AF in a large population. This could help efforts at 
screening and detection of AF, as well as early interventions to reduce stroke and other AF-
related complications. 
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Perspectives 
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: We demonstrate the 
feasibility of AF screening in a large population-based cohort using smart device based 
photoplethysmography (PPG) technology, combined with a clinical care AF management 
pathway. Following entry into a program of integrated AF management using a mobile AF 
application, approximately 80% of high-risk patients were successfully anticoagulated.  
TRANSLATIONAL OUTLOOK: Continuous home-monitoring with smart device-based PPG 
technology could be a feasible approach for AF screening. This would help efforts at screening 
and detection of AF, as well as early interventions to reduce stroke and other AF-related 
complications. This integrated approach should be verified in randomized trials.  
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Figure Legends 
Figure 1: AF screening flow diagram. *MAFA: mobile Atrial Fibrillation Application.  
Figure 2: The notification of “suspected” AF by algorithm . *N>10, 0<T<1, seen AF 
detection in the Method in the text. 
Figure 3: AF screening, confirmation, and transference into MAFA. Inclusion: Adult ≥18 
years; Huawei phone (Android 5.0 or higher); Smart devices: Huawei Watch GT (Version 
1.0.3.52 or higher), Honor Watch (Version 1.0.3.52 or higher), Honor Band 4 (Version 1.0.0.86 
or higher). Exclusion: Adult <18 years; Inability to use smart phone or devices. 
Figure 4: Monitoring time to first AF episode. The monitoring time to first detected AF 
episode were classified by 0-7 days, 8-14 days, 15-21 days, 22-30 days, and >31 days. 
Figure 5: Incident “suspected” and “identified” AF among 187,912 population. The incident 
"suspected" and "identified" AF were shown in relation to age- and sex-proportions. 
Central Illustration: Mobile health devices could be a feasible approach for AF screening, 
and into subsequent AF integrated management. MAFA: mobile Atrial Fibrillation 
Application. 
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Table 1: Baseline characteristics.  
 
 Overall Cohort 
(n=187,912) 
Notification 
(n=424) 
Individuals with 
clinical 
evaluation 
(n=262) 
Identified AF 
(n=227) 
Suspected AF episodes, n 265,139 265,139 203,985 186,956 
Female, n (%) 24938 (13.3) 55(13.0) 43(16.4) 42(18.5) 
Age, mean (SD) 34.7(11.5) 54.1(14.3) 54.9(14.0) 56.1(13.7) 
 ≥65, n (%) 3419 (1.8) 95(22.4) 62(23.7) 58(25.5) 
 55-64, n (%) 7491 (4.0) 112(26.4) 71(27.1) 69(30.4) 
 40-54, n (%) 44432 (23.6) 136(32.1) 82(31.3) 64(28.2) 
 20-39, n (%) 132570 (70.5) 81 (19.1) 47(17.9) 36(15.9) 
Location     
 East China, n (%) 57,177 (30.4) 116 (27.4) 67 (25.6) 58 (25.6) 
 North China, n (%) 32,488 (17.3) 98 (23.1) 71 (27.1) 63 (27.8) 
 Central China, n (%) 26,033 (13.9) 42 (9.9) 25 (9.) 19 (8.4) 
 South China, n (%) 21,333 (11.4) 36 (8.5) 23 (8.8) 20 (8.8) 
25 
 Southwest China, n (%) 17,156 (9.1) 30 (7.1) 15 (5.7) 13 (5.7) 
 Northwest China, n (%) 12,762 (6.8) 30 (7.1) 15 (5.7) 14 (6.2) 
 Northeast China, n (%) 12,805 (6.8) 62 (14.6) 42 (16.0) 36 (15.9) 
 Others, n (%) 8,158 (4.3) 10 (2.4) 4 (1.5) 4 (1.8) 
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Table 2: Risk assessments and anticoagulant use of the 216 patients entered into the MAFA 
programme.  
 
 
(n,%) 
Individuals with newly 
detected AF 
(n=187) 
Individuals with 
known AF  
(n=29) 
p 
CHA2DS2-VASc score     
(mean, SD) 1.04(1.05)  1.24 (1.35) 0.365 
(median, interquartile range) 1(0-2) 1(0-2)  
HAS-BLED score    
(mean, SD) 0.33(0.52)  0.48(0.57) 0.141 
(median, interquartile range) 0(0-1) 0(0-1)  
SAMe-T2T2R score     
(mean, SD) 3.72 (0.63) 3.66 (0.85)  0.644 
(medican, interquartile range) 
 
4(3-4) 4(3-4)  
*Individuals at high risk (n,%) 46 (24.60) 8 (27.59) 0.730 
Anticoagulant use amongst 
patients at high risk  
35(76.09) 8 (100%) 0.266 
27 
 
* Individuals at high risk: CHA2DS2-VASc ≥3 in females, ≥2 in males. 
See Figure 3 for patient flow. 
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Table 3: Oral anticoagulant use in AF patients. 
 Low risk Intermediate risk  High risk 
N (%) 91 (42.1) 71(32.9） 54 (25.0) 
Anticoagulant use at baseline, n% 5 (5.49) 9 (12.68) 43 (79.63) 
Anticoagulant use at 3 months, n% 3 (3.30) 29 (40.85) 42 (77.78) 
p 0.372 <0.001 0.673 
* Low risk: CHA2DS2-VASc of 0 in males, or 1 in females; Intermediate risk: CHA2DS2-VASc 
of 2 in female, 1 in male; High risk: CHA2DS2-VASc ≥3 in females, ≥2 in males. McNemar's 
test was used for testing the difference. 
The reasons for patients with or without oral anticoagulants (OACs) on baseline: 
• Low risk patients with OACs at baseline: 2 patients undergoing AF ablation, with OAC 
used after discharge, 2 patients with current onset acute AF episodes, and 1 patient with 
rheumatic valvular heart disease. 
• High risk patients without OACs at baseline: six patients who were unwilling to accept 
anticoagulants, four patients with antiplatelets (aspirin or clopidogrel), and one patient 
anticoagulated with traditional Chinese medicine. 
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Online Table 1  “Suspected” AF episodes in relation to measurement method 
 
* IQR: interquartile range.  
Kruskal-Wallis test was used for the comparation among different measurement approaches. 
When the subjects downloaded App and had matched smart devices, periodic measurements were 
automatically taken every 10 minutes, and 60-second PPG signals would be continuously collected, per 
measurement.  In addition, subjects could initiate ( dditional) active measurements as needed. 
 
 
  
 Total subjects with 
“suspected” AF (n=424) 
Subjects with “suspected” 
AF followed up (n=262) 
Subjects identified with 
AF (n=227) 
Active measurement 
(median, IQR) 
172.0 (56.5-396.0) 200.5(53.7-518.7) 210.0 (86.0-518.7) 
Automatic periodic 
measurement 
(median, IQR) 
232.5 (57.5-690.2) 286.0 (66.0-860.0) 319.0 (65.0-900.0) 
Active and periodic 
measurement 
(median, IQR) 
1219.5 (263.7-2092.0) 
 
1427.0(362.0-4416.0) 1430.0 (594.0-4461.0) 
P 
 
<0.001 <0.001 <0.001 
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Online Table 2  Users reported adverse events 
 Overall cohort  
Total 186 
  Any device connection and data synchronization issues 123 
  Login and experience issues (any) 63 
Skin irritation, anxiety, pressure 0 
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Online Table 3   Comparison of the performance of smart devices utilized in PPG screening 
 
 
  
Smart devices Planned 
enrolled 
subjects 
Enrolled 
subjects 
AF 
Sinus 
rhythm 
Specificity Sensitivity Accuracy 
HONOR BAND 4 200 264 27 237 99.2% 100% 99.2% 
HONOR WATCH 200 265 24 241 99.2% 100% 99.2% 
HUAWEI WATCH GT 200 212 22 190 98.9% 100% 99.1% 
9 
Online Table 4:  Comparison of the standby time of smart devices with or without PPG screening 
 
Smart devices Battery(mAh) 
Standby time 
without PPG 
screening (days) 
Standby time with 
PPG screening (days) 
HUAWEI WATCH GT 420 30 12 
HONOR WATCH 178 14 5.5 
HUAWEI BAND 3/3PRO 100 12 4.5 
HONOR BAND 4/5 100 14 5 
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OnlineTable 5:  Clinical decision support for 216 identified AF entering the MAFA programme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Risk scores n % 
CHA2DS2-VASc 
 
0 81 37.5 
1 69 31.9 
2 45 20.8 
3 14 6.5 
4 5 2.3 
5 2 .9 
HAS-BLED 
 
0 146 67.6 
1 66 30.6 
2 3 1.4 
3 1 .5 
   
SAMe-T2T2R 
 
2 6 2.8 
3 69 31.9 
4 124 57.4 
5 16 7.4 
6 1 .5 
   
Total 216 100 
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OnlineTable 6  Risk factors of 66573 individuals with C2HEST scores 
 
 
East China 
(n=20095) 
North 
China(n=11574) 
South China 
(n=9224) 
Central China 
(n=7651) 
Southwest 
China 
(n=6077) 
Northwest 
China 
(n=4573) 
Northeast 
China 
(n=4517) 
Others 
(n=2862) 
Hypertension, n (%) 3166 (15.76%) 1829(15.80%) 1490(16.15%) 1245(16.27%) 956(15.73%) 691(15.11%) 753(16.67%) 475(16.60%) 
Diabetes, n (%) 723(3.60%) 424(3.66%) 330(3.58%) 267(3.49%) 222(3.65%) 155(3.39%) 162(3.59%) 110(3.84%) 
COPD/Night snoring, n 
(%) 
6701(33.35%) 3833(33.12%) 3069(33.27%) 2561(33.47%) 2071(34.08%) 1569(34.31%) 1578(34.93%) 891(31.13%) 
HF, n (%) 273(1.36%) 168(1.45%) 138(1.50%) 106(1.39%) 91(1.50%) 61(1.33%) 85(1.88%) 37(1.29%) 
Hyperthyroidism, n (%) 262(1.30%) 156(1.35%) 138(1.50%) 101(1.32%) 73(1.20%) 71(1.55%) 86(1.90%) 37(1.29%) 
CAD, n (%) 569(2.83%) 364(3.14%) 266(2.88%) 228(2.98%) 183(3.01%) 124(2.71%) 137(3.03%) 84(2.94%) 
* C2HEST score: C2: CAD/COPD (1 point each); H: hypertension (1 point); E: elderly (age ≥ 75 years, 2 points); S: systolic HF (2 points); and T: 
thyroid disease (hyperthyroidism, 1 point). The C2HEST score was developed to assess the individual risk of developing AF in the Asian 
population. (Li YG, et al. Chest. 2019 ). COPD: chronic obstructive pulmonary disease. HF: heart failure. CAD: coronary artery disease. 
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Online Figure 1: Flow chart of AF screening and the mAFA II project 
 
* 
MAFA: mobile Atrial Fibrillation Application. PPG: Photoplethysmography (Guo Y, et al. Int J Clin 
Pract. 2019 Apr 19:e13352.) 
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Online Figure 2: The confirmation and follow-up of individuals with “suspected” AF 
*  Once the notification of “suspected” AF was delivered, the participants could choose the MAFA 
hospitals nearby, book the doctors, then go to hospital , receive clinical evaluation. The clinical 
evaluation included that the evaluation of cardiovascular risk factors, medical history, physical 
examination, ECG or 24-hour Holter. 
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Online Figure 3: Enrolment across China (n=187912) 
 
 
 
Data visualization analysis was utilized for the enrolment across China with ECharts.  
Enrolment: October 26, 2018 to May 20, 2019. 
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Online Figure 4: Cardiac rhythm of those with “suspected” AF 
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Online Figure 5: Monitoring method for first “suspected” AF 
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Online Figure 6: The prevalence of detected AF across China 
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Online Figure 7: The informed consent of AF screenig and MAFA II study 
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Online Figure 8: Verification report of the PPG algorithm and smart devices 
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Online Figure 9: The distribution of monitoring tim e in the whole cohort 
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Online Figure 10 Verification report of PPG algorithm  
There were four stages to develop, verify, and validate the PPG algorithm.  
The pilot work has been published as follows: Fan YY, et al. JMIR Mhealth Uhealth. 2019 Mar 5;7(3):e11437.   
The development and testification of PPG algorithm has been presented in the 2019 Cardiac Imaging & Cardiac 
Intervention Summit (http://www.cici.net.cn/2019/), and the validation of PPG algorithm (developed by HUAWEI) 
with 14-day monitoring, “Photoplethysmographi-based mart device for continuous detection of atrial fibrillation in 
a real-world setting”, presented at the 2019 European Society of Cardiology Congress in Paris, France.  
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Online Figure 11 Verification report of smart devices used
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